Neutralizing Antibody in Outpatients with Covid-19 References 1. Tabata S, Imai K, Kawano S, et al. icitinib restrains the immune dysregula- 17. Baum A, Ajithdoss D, Copin R, et al. Clinical characteristics of COVID-19 in tion in severe COVID-19 patients. J Clin REGN-COV2 antibodies prevent and treat 104 people with SARS-CoV-2 infection on Invest 2020 August 18 (Epub ahead of SARS-CoV-2 infection in rhesus macaques the Diamond Princess cruise ship: a retro- print). and hamsters. Science 2020 October 9 spective analysis. Lancet Infect Dis 2020; 10. Stebbing J, Krishnan V, de Bono S, et (Epub ahead of print). 20: 1043-50. al. Mechanism of baricitinib supports ar- 18. Hoffmann M, Kleine-Weber H, Schro- 2. Jehi L, Ji X, Milinovich A, et al. Devel- tificial intelligence-predicted testing in eder S, et al. SARS-CoV-2 cell entry de- opment and validation of a model for in- COVID-19 patients. EMBO Mol Med 2020; pends on ACE2 and TMPRSS2 and is dividualized prediction of hospitalization 12(8): e12697. blocked by a clinically proven protease risk in 4,536 patients with COVID-19. 11. Dastan F, Saffaei A, Haseli S, et al. inhibitor. Cell 2020; 181(2): 271.e8-280.e8. PLoS One 2020; 15(8): e0237419. Promising effects of tocilizumab in 19. Jones BE, Brown-Augsburger PL, Cor- 3. Garg SKL, Kim L, Whitaker M, et al. COVID-19: a non-controlled, prospective bett KS, et al. LY-CoV555, a rapidly isolat- Hospitalization rates and characteristics clinical trial. Int Immunopharmacol ed potent neutralizing antibody, provides of patients hospitalized with laboratory- 2020; 88: 106869. protection in a non-human primate mod- confirmed coronavirus disease 2019 — 12. Farooqi F, Dhawan N, Morgan R, el of SARS-CoV-2 infection. October 1, COVID-NET, 14 states, March 1–30, 2020. Dinh J, Nedd K, Yatzkan G. Treatment of 2020 (https://www . biorxiv . org/ content/ MMWR Morb Mortal Wkly Rep 2020; 69: severe COVID-19 with tocilizumab miti- 10 . 1101/ 2020 . 09 . 30 . 318972v3). preprint. 458-64. gates cytokine storm and averts mechani- 20. Chen J, Qi T, Liu L, et al. Clinical pro- 4. Cavalcanti AB, Zampieri FG, Rosa cal ventilation during acute respiratory gression of patients with COVID-19 in RG, et al. Hydroxychloroquine with or distress: a case report and literature re- Shanghai, China. J Infect 2020; 80(5): e1- without azithromycin in mild-to-moder- view. Trop Med Infect Dis 2020; 5: E112. e6. ate Covid-19. N Engl J Med. DOI: 1 0.1056/ 13. The RECOVERY Collaborative Group. 21. He X, Lau EHY, Wu P, et al. Temporal NEJMoa2019014. Dexamethasone in hospitalized patients dynamics in viral shedding and transmis- 5. Beigel JH, Tomashek KM, Dodd LE. with Covid-19 — preliminary report. N Engl sibility of COVID-19. Nat Med 2020; 26: Remdesivir for the treatment of Covid-19 J Med. DOI: 10.1056/NEJMoa2021436. 672-5. — final report. N Engl J Med. DOI: 14. Sterne JAC, Murthy S, Diaz JV, et al. 22. Liu Y, Yan L-M, Wan L, et al. Viral 10.1056/NEJMoa2007764. Association between administration of sys- dynamics in mild and severe cases of 6. Goldman JD, Lye DCB, Hui DS, et al. temic corticosteroids and mortality among COVID-19. Lancet Infect Dis 2020; 20: 656- Remdesivir for 5 or 10 days in patients critically ill patients with COVID-19: a 7. with severe Covid-19. N Engl J Med. DOI: meta-analysis. JAMA 2020; 324: 1-13. 23. Zhou F, Yu T, Du R, et al. Clinical 10.1056/NEJMoa2015301. 15. Joyner MJ, Senefeld JW, Klassen SA, et course and risk factors for mortality of 7. Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of convalescent plasma on mor- adult inpatients with COVID-19 in Wu- al. Effect of remdesivir vs standard care tality among hospitalized patients with han, China: a retrospective cohort study. on clinical status at 11 days in patients COVID-19: initial three-month experi- Lancet 2020; 395: 1054-62. with moderate COVID-19: a randomized ence. August 12, 2020 (https://www 24. Kim L, Garg S, O’Halloran A, et al. clinical trial. JAMA 2020; 324: 1048-57. . medrxiv . org/ content/ 10 . 1101/ 2020 . 08 . 12 Risk factors for intensive care unit admis- 8. Sims JT, Krishnan V, Chang C-Y, et al. . 20169359v1). preprint. sion and in-hospital mortality among hos- Characterization of the cytokine storm 16. Li L, Zhang W, Hu Y, et al. Effect of pitalized adults identified through the U.S. reflects hyperinflammatory endothelial convalescent plasma therapy on time to Coronavirus Disease 2019 (COVID-19)- dysfunction in COVID-19. J Allergy Clin clinical improvement in patients with se- Associated Hospitalization Surveillance Immunol 2020 September 10 (Epub ahead vere and life-threatening COVID-19: a Network (COVID-NET). Clin Infect Dis of print). randomized clinical trial. JAMA 2020; 2020 July 16 (Epub ahead of print). 9. Bronte V, Ugel S, Tinazzi E, et al. Bar- 324: 460-70. Copyright © 2020 Massachusetts Medical Society. n engl j med nejm.org 9 The New England Journal of Medicine Downloaded from nejm.org on November 19, 2020. For personal use only. No other uses without permission. Copyright © 2020 Massachusetts Medical Society. All rights reserved.